By Jocelyn KaiserMay. 28, 2020 , 2:00 PM Amy Boland has gone through many ups and downs since she noticed lumps under her arms 12 years ago and learned she had cancer of the lymph system. For about 6 years, conventional chemotherapy helped shrink her lymphoma tumors, but they started to grow again. A succession of other cancer therapies, including a bone marrow transplant and a class of drugs called checkpoint inhibitors, either failed or only brought temporary relief. In one elaborate effort, physicians harvested her T cells, engineered those immune cells to kill her lymphoma, and infused them back into her body. The cancer vanished, but 2 years later bounced back. “Nothing was really working,” says oncologist Stephen Schuster of the University of Pennsylvania (UPenn). So in October 2018, Boland joined a clinical trial testing another way to harness her immune system to kill the tumor cells. The idea of the trial, which Schuster co-leads, was to use a molecular rope known as a bispecific antibody to tether her natural T cells to the tumor cells so the immune warriors would attack. Like the engineered T cells she had received earlier, the experimental infusions sometimes made her sick enough… Read full this story
- Pioneering Immunotherapy Targeting Elusive Cancer Cells In Children
- An Innovative New Cancer Therapy Hijacks Bacteria to Fight Tumors
- New Cancer Therapy Shows Promise in Treating Aggressive Brain Tumors
- 50 Foods You Need To Have If You Want To Keep Cancer Away
- Gene Therapy: Latest CAR-T Therapy for Cancer Signals New Era for Life-Saving Treatments
- Local researchers discuss childhood cancer awareness
- Celebrity favorite keto diet may stop a type of lung cancer in its tracks by cutting off its sugar fuel, study finds
- Cure for cancer found? Scientists claim to find a potential cancer-killing virus; studies underway
- 'Blood cleaning' technique uses magnets to remove cancer from the body
- Cancer patient, 62, told his lymphoma was terminal claims the disease is now 'on the run' after being given pioneering 'living drug' treatment
Designer antibodies fight cancer by tethering immune cells to tumor cells have 316 words, post on www.sciencemag.org at May 28, 2020. This is cached page on Bach Thien. If you want remove this page, please contact us.